Real-World study tracks patient adherence to multiple myeloma drug regimens
NCT ID NCT02970747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how faithfully adults with multiple myeloma (a type of blood cancer) follow their prescribed carfilzomib combination treatments in everyday medical practice. It included 359 patients who had already tried at least one prior therapy. The goal was to measure adherence and persistence to the drug regimen, not to test new treatments or compare effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt, 60389, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Engineered immune cells take on incurable blood cancer
- New CAR T-Cell therapy targets Hard-to-Treat myeloma
- Could a simple shot replace hospital stays for myeloma patients?
- New hope for hard-to-treat myeloma: drug duo targets genetic weak spot